Hi Edward and Rene
Just wondering what your thoughts are on the CMB305 clinical trials at MD Anderson for synovial sarcoma? Is it something you would consider in the future should you have further disease progression?
Also did your tumour have NY-ESO? Bisaphic or Monosaphic? and was your fusion type SSX1 or SSX2? ours is Bisaphic SSX1 which i believe is less favourable.
Many thanks again for your time!
Thank you for bringing the CMB305 clinical trial to our attention!
CMB305 targets dendritic cells to activate NY-ESO-1 T cells. NY-ESO-1 is often found in synovial sarcoma cells (Chapter 6, section "A precise target", pg 88-89)
If I have a recurrence, I would not do CMB305, as I've already done treatments to activate T cells that recognize NY-ESO-1 (NY-ESO-1 vaccine - Chapter 6, dendritic vaccine - Chapter 12), and the immune system has memory.
My tumor (both primary and recurrent) did have NY-ESO-1 in it, was monophasic and had a high mitotic index (ie - it grows fast). The SSX1 or SSX2 fusion type was not determined, although it was shown that the SYT gene was broken up in my tumor.